IL6 and non-small cell lung carcinoma: Previous studies have highlighted IL-1β, IL-6, and IL-8 as key mediators of tumor-associated inflammation, with IL-1β expression correlating with disease progression and survival in molecularly defined NSCLC subgroups [25].